Your browser doesn't support javascript.
loading
Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.
Maung, Ko K; Chen, Benny J; Barak, Ian; Li, Zhiguo; Rizzieri, David A; Gasparetto, Cristina; Sullivan, Keith M; Long, Gwynn D; Engemann, Ashley M; Waters-Pick, Barbara; Nichols, Krista Rowe; Lopez, Richard; Kang, Yubin; Sarantopoulos, Stefanie; Sung, Anthony D; Chao, Nelson J; Horwitz, Mitchell E.
Afiliación
  • Maung KK; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Chen BJ; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Barak I; Cancer Center Biostatistics, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
  • Li Z; Cancer Center Biostatistics, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
  • Rizzieri DA; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Gasparetto C; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Sullivan KM; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Long GD; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Engemann AM; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Waters-Pick B; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Nichols KR; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Lopez R; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Kang Y; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Sarantopoulos S; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Sung AD; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Chao NJ; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
  • Horwitz ME; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA. Mitchell.Horwitz@duke.edu.
Bone Marrow Transplant ; 56(1): 137-143, 2021 01.
Article en En | MEDLINE | ID: mdl-32624583
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Límite: Adult / Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Límite: Adult / Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido